

Filed: June 25, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner,

v.

BIOGEN MA, INC.
Patent Owner.

Patent No. 8,399,514

Inter Partes Review IPR2018-01403

**PETITIONER'S NOTICE OF DEPOSITION OF
RICHARD C. BRUNDAGE, PHARM.D, PH.D.**

Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc., hereby provides notice that it will cross-examine Dr. Richard C. Brundage, a witness of Patent Owner Biogen MA, Inc. The cross-examination will begin at 9:00 a.m. on July 10, 2019 at the law offices of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC 20001. The parties have agreed on this date for the cross-examination of Dr. Brundage.

The cross-examination will be recorded by stenographic means by a court reporter licensed to administer oaths, and will also be recorded using audio and/or visual means.

Respectfully submitted,

PERKINS COIE LLP

Dated: June 25, 2019

By: /s/ Emily J. Greb

Emily J. Greb
Reg. No. 68,244
Perkins Coie LLP
33 East Main Street, Suite 201
Madison, WI 53703
Telephone: (608) 663-7494
E-mail: EGreb@perkinscoie.com

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing PETITIONER'S NOTICE OF DEPOSITION OF RICHARD C. BRUNDAGE, PHARM.D, PH.D. was served electronically via e-mail as follows:

Patent Owner:

Barbara C. McCurdy
Mark J. Feldstein
Erin M. Sommers
Pier D. DeRoo
Finnegan, Henderson, Farabow, Garrett
& Dunner, LLP
901 New York Avenue, NW
Washington, DC 20001
(202) 408-4047
barbara.mccurdy@finnegan.com
mark.feldstein@finnegan.com
erin.sommers@finnegan.com
pier.deroo@finnegan.com

Dated: June 25, 2019

/s/ Emily J. Greb
Emily J. Greb
Reg. No. 68,244